Midregional proadrenomedullin for prognosis in community-acquired pneumonia: A systematic review

Rodrigo Cavallazzi, Karim El-Kersh, Emran Abu-Atherah, Sonal Singh, Yoon K. Loke, Timothy Wiemken, Julio Ramirez

Research output: Contribution to journalArticle

Abstract

SummaryIntroduction The initial prognostic assessment of patients with community-acquired pneumonia (CAP) has important clinical implications. We hypothesized that midregional proadrenomedullin (MR-proADM) is a valuable test for the prediction of outcomes in patients with CAP. Methods We performed a systemic review of the literature and a meta-analysis to evaluate the prognostic value of MR-proADM for short and long-term mortality in patients with CAP. Results Twelve studies were included in the systematic review. Elevated MR-proADM was associated with an increase in short-term mortality (OR = 6.8; 95% CI: 4.65-10.13; P value <0.001) and complications (OR = 5.0; 95% CI: 3.86-6.49; P value <0.001). The pooled analysis of 4 studies showed an improvement in the discriminant ability by 8% (95% CI: 2%-14%) when MR-proADM was added to CURB-65/CRB-65. Studies that reported long-term prognosis indicated an increased risk of death in patients with elevated MR-proADM. Conclusion Elevated level of MR-proADM is significantly associated with both short-term mortality and complications in patients with CAP. Studies also indicate that MR-proADM has prognostic value for prediction of long-term mortality in these patients. The addition of MR-proADM improves the discriminant ability of CURB-65/CRB-65.

Original languageEnglish (US)
Pages (from-to)1569-1580
Number of pages12
JournalRespiratory Medicine
Volume108
Issue number11
DOIs
StatePublished - Nov 1 2014

Fingerprint

Pneumonia
Mortality
proadrenomedullin
Meta-Analysis

Keywords

  • Epidemiology
  • Meta-analysis
  • Pneumonia
  • Prognosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

Cavallazzi, R., El-Kersh, K., Abu-Atherah, E., Singh, S., Loke, Y. K., Wiemken, T., & Ramirez, J. (2014). Midregional proadrenomedullin for prognosis in community-acquired pneumonia: A systematic review. Respiratory Medicine, 108(11), 1569-1580. https://doi.org/10.1016/j.rmed.2014.09.018

Midregional proadrenomedullin for prognosis in community-acquired pneumonia : A systematic review. / Cavallazzi, Rodrigo; El-Kersh, Karim; Abu-Atherah, Emran; Singh, Sonal; Loke, Yoon K.; Wiemken, Timothy; Ramirez, Julio.

In: Respiratory Medicine, Vol. 108, No. 11, 01.11.2014, p. 1569-1580.

Research output: Contribution to journalArticle

Cavallazzi, R, El-Kersh, K, Abu-Atherah, E, Singh, S, Loke, YK, Wiemken, T & Ramirez, J 2014, 'Midregional proadrenomedullin for prognosis in community-acquired pneumonia: A systematic review', Respiratory Medicine, vol. 108, no. 11, pp. 1569-1580. https://doi.org/10.1016/j.rmed.2014.09.018
Cavallazzi R, El-Kersh K, Abu-Atherah E, Singh S, Loke YK, Wiemken T et al. Midregional proadrenomedullin for prognosis in community-acquired pneumonia: A systematic review. Respiratory Medicine. 2014 Nov 1;108(11):1569-1580. https://doi.org/10.1016/j.rmed.2014.09.018
Cavallazzi, Rodrigo ; El-Kersh, Karim ; Abu-Atherah, Emran ; Singh, Sonal ; Loke, Yoon K. ; Wiemken, Timothy ; Ramirez, Julio. / Midregional proadrenomedullin for prognosis in community-acquired pneumonia : A systematic review. In: Respiratory Medicine. 2014 ; Vol. 108, No. 11. pp. 1569-1580.
@article{985479687b4c401ba59b8b43a6c6e7d7,
title = "Midregional proadrenomedullin for prognosis in community-acquired pneumonia: A systematic review",
abstract = "SummaryIntroduction The initial prognostic assessment of patients with community-acquired pneumonia (CAP) has important clinical implications. We hypothesized that midregional proadrenomedullin (MR-proADM) is a valuable test for the prediction of outcomes in patients with CAP. Methods We performed a systemic review of the literature and a meta-analysis to evaluate the prognostic value of MR-proADM for short and long-term mortality in patients with CAP. Results Twelve studies were included in the systematic review. Elevated MR-proADM was associated with an increase in short-term mortality (OR = 6.8; 95{\%} CI: 4.65-10.13; P value <0.001) and complications (OR = 5.0; 95{\%} CI: 3.86-6.49; P value <0.001). The pooled analysis of 4 studies showed an improvement in the discriminant ability by 8{\%} (95{\%} CI: 2{\%}-14{\%}) when MR-proADM was added to CURB-65/CRB-65. Studies that reported long-term prognosis indicated an increased risk of death in patients with elevated MR-proADM. Conclusion Elevated level of MR-proADM is significantly associated with both short-term mortality and complications in patients with CAP. Studies also indicate that MR-proADM has prognostic value for prediction of long-term mortality in these patients. The addition of MR-proADM improves the discriminant ability of CURB-65/CRB-65.",
keywords = "Epidemiology, Meta-analysis, Pneumonia, Prognosis",
author = "Rodrigo Cavallazzi and Karim El-Kersh and Emran Abu-Atherah and Sonal Singh and Loke, {Yoon K.} and Timothy Wiemken and Julio Ramirez",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/j.rmed.2014.09.018",
language = "English (US)",
volume = "108",
pages = "1569--1580",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",
number = "11",

}

TY - JOUR

T1 - Midregional proadrenomedullin for prognosis in community-acquired pneumonia

T2 - A systematic review

AU - Cavallazzi, Rodrigo

AU - El-Kersh, Karim

AU - Abu-Atherah, Emran

AU - Singh, Sonal

AU - Loke, Yoon K.

AU - Wiemken, Timothy

AU - Ramirez, Julio

PY - 2014/11/1

Y1 - 2014/11/1

N2 - SummaryIntroduction The initial prognostic assessment of patients with community-acquired pneumonia (CAP) has important clinical implications. We hypothesized that midregional proadrenomedullin (MR-proADM) is a valuable test for the prediction of outcomes in patients with CAP. Methods We performed a systemic review of the literature and a meta-analysis to evaluate the prognostic value of MR-proADM for short and long-term mortality in patients with CAP. Results Twelve studies were included in the systematic review. Elevated MR-proADM was associated with an increase in short-term mortality (OR = 6.8; 95% CI: 4.65-10.13; P value <0.001) and complications (OR = 5.0; 95% CI: 3.86-6.49; P value <0.001). The pooled analysis of 4 studies showed an improvement in the discriminant ability by 8% (95% CI: 2%-14%) when MR-proADM was added to CURB-65/CRB-65. Studies that reported long-term prognosis indicated an increased risk of death in patients with elevated MR-proADM. Conclusion Elevated level of MR-proADM is significantly associated with both short-term mortality and complications in patients with CAP. Studies also indicate that MR-proADM has prognostic value for prediction of long-term mortality in these patients. The addition of MR-proADM improves the discriminant ability of CURB-65/CRB-65.

AB - SummaryIntroduction The initial prognostic assessment of patients with community-acquired pneumonia (CAP) has important clinical implications. We hypothesized that midregional proadrenomedullin (MR-proADM) is a valuable test for the prediction of outcomes in patients with CAP. Methods We performed a systemic review of the literature and a meta-analysis to evaluate the prognostic value of MR-proADM for short and long-term mortality in patients with CAP. Results Twelve studies were included in the systematic review. Elevated MR-proADM was associated with an increase in short-term mortality (OR = 6.8; 95% CI: 4.65-10.13; P value <0.001) and complications (OR = 5.0; 95% CI: 3.86-6.49; P value <0.001). The pooled analysis of 4 studies showed an improvement in the discriminant ability by 8% (95% CI: 2%-14%) when MR-proADM was added to CURB-65/CRB-65. Studies that reported long-term prognosis indicated an increased risk of death in patients with elevated MR-proADM. Conclusion Elevated level of MR-proADM is significantly associated with both short-term mortality and complications in patients with CAP. Studies also indicate that MR-proADM has prognostic value for prediction of long-term mortality in these patients. The addition of MR-proADM improves the discriminant ability of CURB-65/CRB-65.

KW - Epidemiology

KW - Meta-analysis

KW - Pneumonia

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84922439923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922439923&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2014.09.018

DO - 10.1016/j.rmed.2014.09.018

M3 - Article

C2 - 25448309

AN - SCOPUS:84922439923

VL - 108

SP - 1569

EP - 1580

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - 11

ER -